IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
INR 61.65
(3.88%)
INR 61.65
(3.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.94 Billion INR | -6.9% |
| 2022 | 1.8 Billion INR | -16.67% |
| 2021 | 2.16 Billion INR | -60.92% |
| 2020 | 5.53 Billion INR | 2.77% |
| 2019 | 5.38 Billion INR | 42.66% |
| 2018 | 3.77 Billion INR | 315.21% |
| 2017 | 908.5 Million INR | 1558.63% |
| 2016 | 54.77 Million INR | 114.21% |
| 2015 | -385.5 Million INR | 48.9% |
| 2014 | -754.38 Million INR | -1584.33% |
| 2013 | 50.82 Million INR | 71.79% |
| 2012 | 29.58 Million INR | -93.71% |
| 2011 | 469.96 Million INR | 2.52% |
| 2010 | 458.39 Million INR | 55.28% |
| 2009 | 295.21 Million INR | 13.47% |
| 2008 | 260.17 Million INR | -11.59% |
| 2007 | 294.26 Million INR | 91.68% |
| 2006 | 153.52 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 342.9 Million INR | 241.37% |
| 2023 FY | 1.67 Billion INR | -6.9% |
| 2023 Q1 | 580.7 Million INR | -36.82% |
| 2023 Q2 | 556.2 Million INR | -4.22% |
| 2023 Q3 | 363.9 Million INR | -34.57% |
| 2023 Q4 | 330.9 Million INR | -9.07% |
| 2022 FY | 1.8 Billion INR | -16.67% |
| 2022 Q2 | 256.5 Million INR | -42.76% |
| 2022 Q3 | 375.9 Million INR | 46.55% |
| 2022 Q1 | 448.1 Million INR | 27.26% |
| 2022 Q4 | 919.1 Million INR | 144.51% |
| 2021 Q1 | 998.3 Million INR | -1.57% |
| 2021 Q2 | 330 Million INR | -66.94% |
| 2021 FY | 2.16 Billion INR | -60.92% |
| 2021 Q3 | 480.8 Million INR | 45.7% |
| 2021 Q4 | 352.1 Million INR | -26.77% |
| 2020 Q3 | 1.47 Billion INR | -8.91% |
| 2020 FY | 5.53 Billion INR | 2.77% |
| 2020 Q1 | 1.42 Billion INR | 11.91% |
| 2020 Q4 | 1.01 Billion INR | -31.14% |
| 2020 Q2 | 1.61 Billion INR | 13.25% |
| 2019 Q2 | 1.24 Billion INR | -8.78% |
| 2019 Q3 | 1.5 Billion INR | 21.34% |
| 2019 Q4 | 1.27 Billion INR | -15.27% |
| 2019 FY | 5.38 Billion INR | 42.66% |
| 2019 Q1 | 1.36 Billion INR | -8.86% |
| 2018 Q4 | 1.49 Billion INR | 17.39% |
| 2018 Q2 | 669.4 Million INR | 109.51% |
| 2018 FY | 3.77 Billion INR | 315.21% |
| 2018 Q1 | 319.5 Million INR | 18.91% |
| 2018 Q3 | 1.27 Billion INR | 89.92% |
| 2017 Q1 | 31.7 Million INR | -83.24% |
| 2017 FY | 908.5 Million INR | 1558.63% |
| 2017 Q4 | 268.7 Million INR | 181.07% |
| 2017 Q3 | 95.6 Million INR | 63.7% |
| 2017 Q2 | 58.4 Million INR | 84.23% |
| 2016 FY | 54.77 Million INR | 114.21% |
| 2016 Q2 | 12.9 Million INR | 23.99% |
| 2016 Q3 | 13.4 Million INR | 3.88% |
| 2016 Q1 | 10.4 Million INR | -34.63% |
| 2016 Q4 | 189.1 Million INR | 1311.19% |
| 2015 Q2 | -146.25 Million INR | 25.98% |
| 2015 Q4 | 15.91 Million INR | 127.64% |
| 2015 Q1 | -197.59 Million INR | 36.13% |
| 2015 Q3 | -57.57 Million INR | 60.64% |
| 2015 FY | -385.5 Million INR | 48.9% |
| 2014 Q4 | -309.36 Million INR | 3.61% |
| 2014 Q3 | -320.95 Million INR | -124.22% |
| 2014 Q1 | 19.08 Million INR | 95.15% |
| 2014 FY | -754.38 Million INR | -1584.33% |
| 2014 Q2 | -143.14 Million INR | -850.05% |
| 2013 Q4 | 9.77 Million INR | -26.22% |
| 2013 Q2 | 15.23 Million INR | 21.35% |
| 2013 Q1 | 12.55 Million INR | -89.34% |
| 2013 Q3 | 13.25 Million INR | -13.0% |
| 2013 FY | 50.82 Million INR | 71.79% |
| 2012 Q4 | 117.81 Million INR | -26.48% |
| 2012 Q3 | 160.25 Million INR | 10.94% |
| 2012 Q2 | 144.44 Million INR | -6.42% |
| 2012 Q1 | 154.36 Million INR | 0.0% |
| 2012 FY | 29.58 Million INR | -93.71% |
| 2011 FY | 469.96 Million INR | 2.52% |
| 2010 FY | 458.39 Million INR | 55.28% |
| 2009 FY | 295.21 Million INR | 13.47% |
| 2008 FY | 260.17 Million INR | -11.59% |
| 2007 FY | 294.26 Million INR | 91.68% |
| 2006 FY | 153.52 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 14.17% |
| Hester Biosciences Limited | 364.77 Million INR | -1254.881% |
| Aarti Drugs Limited | 7.14 Billion INR | 30.866% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -57.993% |
| Albert David Limited | 1.33 Billion INR | -270.353% |
| Alembic Limited | 767.77 Million INR | -543.708% |
| Alkem Laboratories Limited | 19.46 Billion INR | 74.606% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -1979.517% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -23826.22% |
| Brooks Laboratories Limited | -72.25 Million INR | 6940.226% |
| Eris Lifesciences Limited | 5.18 Billion INR | 4.622% |
| FDC Limited | 3.03 Billion INR | -62.908% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 44.959% |
| Gufic Biosciences Limited | 2.89 Billion INR | -70.786% |
| Hikal Limited | 1.49 Billion INR | -230.759% |
| Ind-Swift Limited | 1.22 Billion INR | -303.128% |
| Innova Captab Limited | 2.53 Billion INR | -95.081% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -2209.008% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 4.756% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -159.252% |
| Lupin Limited | 27.75 Billion INR | 82.195% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -17899.126% |
| Medico Remedies Limited | 277.11 Million INR | -1683.428% |
| Morepen Laboratories Limited | 4.17 Billion INR | -18.409% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -27.03% |
| Orchid Pharma Limited | 2.36 Billion INR | -109.32% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -77.394% |
| RPG Life Sciences Limited | 2.29 Billion INR | -115.6% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2275.487% |
| Sigachi Industries Limited | 1.47 Billion INR | -235.315% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 228.272% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -7.261% |
| Themis Medicare Limited | 1.3 Billion INR | -279.263% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -78422.402% |
| Wanbury Limited | 1.7 Billion INR | -189.49% |
| Windlas Biotech Limited | 1.29 Billion INR | -280.494% |
| ZIM Laboratories Limited | 1.09 Billion INR | -350.063% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -145.999% |
| Ipca Laboratories Limited | 29.59 Billion INR | 83.301% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.262% |
| Venus Remedies Limited | 534.65 Million INR | -824.379% |
| Sakar Healthcare Limited | 495.5 Million INR | -897.405% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 95.271% |
| Divi's Laboratories Limited | 18.31 Billion INR | 73.008% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | -10.467% |
| Mankind Pharma Limited | 40.86 Billion INR | 87.907% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | -25.163% |
| Neuland Laboratories Limited | 5.31 Billion INR | 7.068% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 34.468% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 23.994% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 89.112% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -695.811% |
| Wockhardt Limited | 140 Million INR | -3430.143% |
| Bal Pharma Limited | 214.56 Million INR | -2203.315% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 92.703% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -301.478% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -795.993% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 31.599% |
| Shilpa Medicare Limited | 3.76 Billion INR | -31.387% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 74.884% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -174485.086% |
| Granules India Limited | 6.52 Billion INR | 24.295% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1882.821% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 80.493% |
| NATCO Pharma Limited | 25.96 Billion INR | 80.964% |
| Suven Life Sciences Limited | -1.22 Billion INR | 503.174% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 5.427% |
| Indoco Remedies Limited | 1.52 Billion INR | -224.206% |
| Alpa Laboratories Limited | 61.51 Million INR | -7934.138% |
| Lasa Supergenerics Limited | -458 Million INR | 1179.071% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 220.101% |